Improving Type 2 Diabetes Therapy Adherence and Persistence Around the World
In Brazil, there are over 11.5 million people living with type 2 diabetes (T2D)—a figure expected to double by 2040. To date, there has been no coordinated, national initiatives to address the growing economic and societal burden of the condition, possibly as a result of the fragmentation and complexity of the Brazilian healthcare system. As such, there are significant opportunities to roll out T2D therapy compliance and persistence improvement solutions in both the public and private healthcare sectors.
In Germany, approximately 270,000 people are diagnosed with type 2 diabetes (T2D) annually and 8 million people are projected to live with the condition by 2030. The organisation of the German healthcare system promotes local rather than national initiatives when it comes to the management of the condition and the implementation of therapy adherence and persistence improvement solutions. These local initiatives could easily serve as scalable pilot projects that could be rolled out to other States.
Kingdom of Saudi Arabia
In Saudi Arabia, type 2 diabetes (T2D) prevalence is currently approximately 25% and the number of individuals suffering from the condition is forecasted to more than double by 2035. While the government is starting to recognize the growing burden of the condition, there remain opportunities to improve T2D therapy compliance and persistence, which include up-skilling primary-care HCPs and improving diabetes education.
In Mexico, approximately 2 out of 5 people either have or are at high risk of developing type 2 diabetes (T2D). By 2040, 20.6 million people are projected to live with the condition in the country. The government and healthcare providers have started to recognize the growing economic and societal burden of the condition, which has resulted in a national strategy to prevent and control T2D and multidisciplinary care programs. These initiatives create opportunities to further improve therapy adherence and persistence by up-skilling of primary-care HCPs and promoting T2D education.
In the U.K., policy makers and healthcare providers are starting to recognise and react to the societal and economic burden of type 2 diabetes (T2D). However, there are still opportunities to improve T2D therapy adherence and persistence, which drives a significant amount of this burden. In order to further promote T2D therapy adherence and persistence in the U.K., access to all forms of diabetes education could be increased while interactions between healthcare professionals and people with diabetes could be optimized.
In the U.S., an estimated 400,000 seniors are diagnosed with type 2 diabetes (T2D) every year and 17.2 million seniors are expected to live with the condition by 2025. Recognizing the growing burden of T2D, policy makers and healthcare providers are already promoting adherence and persistence improvements in the Medicare population. However, there are further opportunities to tailor and integrate existing adherence and persistence improvement solutions into the lives of seniors living with the condition.